Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19

Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Hideta, Miyagi, Kazuya, Otsuki, Mariko, Higure, Yuuri, Nishiyama, Naoya, Kinjo, Takeshi, Nakamatsu, Masashi, Haranaga, Shusaku, Tateyama, Masao, Fujita, Jiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725631/
https://www.ncbi.nlm.nih.gov/pubmed/32963155
http://dx.doi.org/10.2169/internalmedicine.5244-20
_version_ 1783620739142778880
author Nakamura, Hideta
Miyagi, Kazuya
Otsuki, Mariko
Higure, Yuuri
Nishiyama, Naoya
Kinjo, Takeshi
Nakamatsu, Masashi
Haranaga, Shusaku
Tateyama, Masao
Fujita, Jiro
author_facet Nakamura, Hideta
Miyagi, Kazuya
Otsuki, Mariko
Higure, Yuuri
Nishiyama, Naoya
Kinjo, Takeshi
Nakamatsu, Masashi
Haranaga, Shusaku
Tateyama, Masao
Fujita, Jiro
author_sort Nakamura, Hideta
collection PubMed
description Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.
format Online
Article
Text
id pubmed-7725631
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-77256312020-12-21 Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19 Nakamura, Hideta Miyagi, Kazuya Otsuki, Mariko Higure, Yuuri Nishiyama, Naoya Kinjo, Takeshi Nakamatsu, Masashi Haranaga, Shusaku Tateyama, Masao Fujita, Jiro Intern Med Case Report Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor. The Japanese Society of Internal Medicine 2020-09-19 2020-11-15 /pmc/articles/PMC7725631/ /pubmed/32963155 http://dx.doi.org/10.2169/internalmedicine.5244-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Nakamura, Hideta
Miyagi, Kazuya
Otsuki, Mariko
Higure, Yuuri
Nishiyama, Naoya
Kinjo, Takeshi
Nakamatsu, Masashi
Haranaga, Shusaku
Tateyama, Masao
Fujita, Jiro
Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
title Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
title_full Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
title_fullStr Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
title_full_unstemmed Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
title_short Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
title_sort acute hypertriglyceridaemia caused by tocilizumab in a patient with severe covid-19
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725631/
https://www.ncbi.nlm.nih.gov/pubmed/32963155
http://dx.doi.org/10.2169/internalmedicine.5244-20
work_keys_str_mv AT nakamurahideta acutehypertriglyceridaemiacausedbytocilizumabinapatientwithseverecovid19
AT miyagikazuya acutehypertriglyceridaemiacausedbytocilizumabinapatientwithseverecovid19
AT otsukimariko acutehypertriglyceridaemiacausedbytocilizumabinapatientwithseverecovid19
AT higureyuuri acutehypertriglyceridaemiacausedbytocilizumabinapatientwithseverecovid19
AT nishiyamanaoya acutehypertriglyceridaemiacausedbytocilizumabinapatientwithseverecovid19
AT kinjotakeshi acutehypertriglyceridaemiacausedbytocilizumabinapatientwithseverecovid19
AT nakamatsumasashi acutehypertriglyceridaemiacausedbytocilizumabinapatientwithseverecovid19
AT haranagashusaku acutehypertriglyceridaemiacausedbytocilizumabinapatientwithseverecovid19
AT tateyamamasao acutehypertriglyceridaemiacausedbytocilizumabinapatientwithseverecovid19
AT fujitajiro acutehypertriglyceridaemiacausedbytocilizumabinapatientwithseverecovid19

Ejemplares similares